07:16 AM EDT, 03/11/2025 (MT Newswires) -- Legend Biotech ( LEGN ) reported Tuesday a Q4 adjusted net loss of $0.15 per diluted share, narrower than its loss of $0.24 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.25.

Revenue for the quarter ended Dec. 31 was $186.5 million, up from $79.5 million a year earlier.

Analysts surveyed by FactSet expected $178.1 million.

As of Dec. 31, the company said it had approximately $1.1 billion of cash and cash equivalents and time deposits, and expected it could fund operations through Q2 of fiscal 2026.